A new vaccine that targets the immune system to recognize and fight lung cancer is being tested on UK patients in a world-first trial, it was revealed in London Friday.
The treatment similar to covid vaccines is expected to improve survival rates for people fighting the disease that kills 35,000
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
